A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Exclusion Criteria

• •Treatment with any investigational cellular therapy prior to enrollment. Treatment with an approved anti-CD19 CAR T cell therapy in an investigational setting may be permitted after discussion with and approval of the Sponsor.
• •Progression within 6 weeks of prior anti-CD19 CAR T cell therapy.
• •Residual toxicities or end-organ damage to vital organs from prior therapy that could put a subject at undue risk based on Investigator's assessment. Toxicities related to prior cytokine release syndrome (CRS) or neurotoxicity must be resolved.
• •If a subject has received prior anti-CD19 CAR T therapy, development of ≥ Grade 3 CAR T related CRS or ≥ Grade 3 neurotoxicity that in the opinion of the Investigator would cause unacceptable risk of toxicity to the subject upon treatment with bbT369.
• •Primary central nervous system (CNS) lymphoma or a history or presence of clinically relevant CNS pathology.
• •Active autoimmune disease requiring systemic immunosuppressive and/or cytotoxic therapy within the past two years.
• •Treatment with any prior anti-CD79a therapy.
• •Previous history of an allogeneic bone marrow transplantation. Autologous stem cell transplantation (ASCT) is permitted.